ResMeds $290 Million Volume Ranks 333rd as Stock Dips 1.13% on OSA Study Warning

On August 27, 2025, ResMed (RMD) saw a trading volume of $290 million, ranking 333rd on the stock market. The stock closed down 1.13%, reflecting investor reaction to a major study on obstructive sleep apnea (OSA) released by the company.

The study, published in The Lancet Respiratory Medicine, projects that OSA will affect nearly 77 million U.S. adults by 2050, a 35% increase from 2020. The research highlights a growing prevalence among both men and women, driven by factors such as an aging population and rising BMI. ResMed emphasized the need for expanded screening, early diagnosis, and home-based treatment solutions to address the escalating public health challenge.

Key findings include a 65% increase in OSA cases among women, reaching 30.4 million by 2050, and a 19% rise in men to 45.9 million cases. The study also notes that emerging GLP-1 therapies are expected to have a minimal impact, reducing cases by less than 5%. ResMed's research underscores the urgent demand for scalable diagnostic tools and long-term care strategies, aligning with its focus on home healthcare innovation.

Separately, recent market activity includes the launch of ENGO 2 smart eyewear, Healthy Extracts' new health supplements, and legal actions against Palantir. The Smart Shelves market is projected to grow significantly, while Chesapeake Utilities Corp's leadership remains stable. These developments span technology, health, and retail sectors.